Technical Analysis for CCCC - C4 Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 6.04 | 1.17% | 0.07 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 20 DMA | Bullish | 0.00% | |
Crossed Above 50 DMA | Bullish | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Fell Below 20 DMA | Bearish | 1.17% | |
Fell Below 50 DMA | Bearish | 1.17% | |
Gapped Up | Strength | 1.17% | |
20 DMA Support | Bullish | -0.82% | |
50 DMA Support | Bullish | -0.82% | |
MACD Bullish Centerline Cross | Bullish | -0.82% |
Alert | Time |
---|---|
Possible NR7 | about 6 hours ago |
Possible Inside Day | about 6 hours ago |
Up 3% | about 9 hours ago |
60 Minute Opening Range Breakout | about 9 hours ago |
20 DMA Resistance | about 10 hours ago |
Get a Trading Assistant
- Earnings date: 10/30/2024
C4 Therapeutics, Inc. Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Disease Treatment Of Cancer Non Small Cell Lung Cancer Melanoma Colorectal Cancer Multiple Myeloma NSCLC Synovial Sarcoma Treatment Of Various Cancers Peripheral T Cell Lymphoma
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 11.88 |
52 Week Low | 1.06 |
Average Volume | 973,031 |
200-Day Moving Average | 6.47 |
50-Day Moving Average | 5.97 |
20-Day Moving Average | 6.03 |
10-Day Moving Average | 5.88 |
Average True Range | 0.48 |
RSI (14) | 51.69 |
ADX | 16.19 |
+DI | 22.61 |
-DI | 15.27 |
Chandelier Exit (Long, 3 ATRs) | 5.71 |
Chandelier Exit (Short, 3 ATRs) | 6.40 |
Upper Bollinger Bands | 6.79 |
Lower Bollinger Band | 5.28 |
Percent B (%b) | 0.5 |
BandWidth | 24.95 |
MACD Line | 0.01 |
MACD Signal Line | 0.00 |
MACD Histogram | 0.0149 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 6.52 | ||||
Resistance 3 (R3) | 6.54 | 6.39 | 6.44 | ||
Resistance 2 (R2) | 6.39 | 6.27 | 6.39 | 6.41 | |
Resistance 1 (R1) | 6.22 | 6.20 | 6.31 | 6.20 | 6.39 |
Pivot Point | 6.07 | 6.07 | 6.12 | 6.07 | 6.07 |
Support 1 (S1) | 5.90 | 5.95 | 5.99 | 5.88 | 5.69 |
Support 2 (S2) | 5.75 | 5.88 | 5.75 | 5.67 | |
Support 3 (S3) | 5.58 | 5.75 | 5.64 | ||
Support 4 (S4) | 5.56 |